These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6126231)

  • 41. Review of haloperidol blood level and clinical response: looking through the window.
    Volavka J; Cooper TB
    J Clin Psychopharmacol; 1987 Feb; 7(1):25-30. PubMed ID: 3546403
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low serum neuroleptic levels predict relapse in schizophrenic patients.
    Brown WA; Laughren T; Chisholm E; Williams BW
    Arch Gen Psychiatry; 1982 Sep; 39(9):998-1000. PubMed ID: 6126172
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The "the therapeutic window" of neuroleptic levels in the erythrocytes of schizophrenics (proceedings)].
    Yesavage JA
    Ann Med Psychol (Paris); 1979; 137(3-4):251. PubMed ID: 40511
    [No Abstract]   [Full Text] [Related]  

  • 44. Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients.
    Kucharski LT; Alexander P; Tune L; Coyle J
    Psychopharmacology (Berl); 1984; 82(3):194-8. PubMed ID: 6144127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma level monitoring of antipsychotic drugs. Clinical utility.
    Dahl SG
    Clin Pharmacokinet; 1986; 11(1):36-61. PubMed ID: 2868820
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma neuroleptic concentration: in search of a therapeutic window.
    Potkin S; Hahn R; Sramek J
    Clin Neuropharmacol; 1986; 9 Suppl 4():256-8. PubMed ID: 2882840
    [No Abstract]   [Full Text] [Related]  

  • 47. Lack of relationship of neuroleptic dose and blood serum levels to neuropsychological performance on the LNNB in chronic schizophrenia.
    Puente AE; Tune L
    Int J Neurosci; 1996 Oct; 87(1-2):107-10. PubMed ID: 8913825
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phenothiazine levels in plasma and red blood cells. Their relationship to clinical improvement in schizophrenia.
    Casper R; Garver DL; Dekirmenjian H; Chang S; Davis JM
    Arch Gen Psychiatry; 1980 Mar; 37(3):301-5. PubMed ID: 6102458
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical use of the radioreceptor assay for neuroleptics.
    Cohen BM; Lipinski JF; Harris PQ; Pope HG; Friedman M
    Psychiatry Res; 1980 May; 2(2):173-8. PubMed ID: 6106254
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients.
    Orr MW; Knox JM; Allen R; Gelder MG; Grahame-Smith DG
    Br J Clin Pharmacol; 1981 Mar; 11(3):255-9. PubMed ID: 6111333
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuroleptic blood levels and clinical response.
    Rockland LH
    Can J Psychiatry; 1986 May; 31(4):299-303. PubMed ID: 2871920
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dosage of conventional neuroleptic medication and subjective cognitive functioning in schizophrenia.
    Krausz M; Moritz S; Lambert M; Naber D
    Int Clin Psychopharmacol; 2000 Mar; 15(2):77-81. PubMed ID: 10759338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroleptic bioavailability, psychosocial factors, and clinical status: a 1-year study of schizophrenic outpatients after dose reduction.
    Faraone SV; Curran JP; Laughren T; Faltus F; Johnston R; Brown WA
    Psychiatry Res; 1986 Dec; 19(4):311-22. PubMed ID: 2880360
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Haloperidol blood levels during dosage reduction in chronic schizophrenic patients.
    Goldman Z; Ebstein RP; Lerer B; Zohar J; Hermoni M; Belmaker RH
    Neuropsychobiology; 1981; 7(6):281-4. PubMed ID: 7312145
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interactions between procyclidine and neuroleptic drugs. Some pharmacological and clinical aspects.
    Bamrah JS; Kumar V; Krska J; Soni SD
    Br J Psychiatry; 1986 Dec; 149():726-33. PubMed ID: 2878700
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of dosage and plasma levels in neuroleptic relapse prevention.
    Marder SR
    Acta Psychiatr Scand Suppl; 1994; 382():25-7. PubMed ID: 7916525
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of plasma apolipoproteins D with RBC membrane arachidonic acid levels in schizophrenia.
    Yao JK; Thomas EA; Reddy RD; Keshavan MS
    Schizophr Res; 2005 Jan; 72(2-3):259-66. PubMed ID: 15560970
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Electric convulsive therapy (ECT) increases plasma and red blood cell haloperidol neuroleptic activities.
    Aoba A; Kakita Y; Yamaguchi N; Shido M; Shibata M; Kitani K; Hasegawa K
    Life Sci; 1983 Oct; 33(18):1797-803. PubMed ID: 6645778
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 3H-spiperone binding to lymphocytes in neuroleptic-naive-schizophrenia and the effect of neuroleptic treatment.
    Laufer N; Spivak B; Holdengreber V; Zipser J; Kosower N; Ragolsky M; Weizman A
    Clin Neuropharmacol; 1999; 22(2):110-4. PubMed ID: 10202608
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of neuroleptic treatment and of high dosage diazepam therapy on beta-endorphin immunoreactivity in plasma of schizophrenic patients.
    Gramsch C; Emrich HM; John S; Haas S; Beckmann H; Zaudig M; von Zerssen D
    J Neural Transm; 1984; 59(2):133-41. PubMed ID: 6144724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.